Form 4 for NVCR NovoCure Ltd
Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-27 · accession 0001562180-25-001834 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-03-03 | 2025-02-27+ | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15.0K | 149.0K | -9% | -$296.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-02-28 | S | D | 2,770 | $18.28 | 146,200 | D | — | — | (F3) On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Ordinary Shares | 2025-02-27 | S | D | 10,277 | $19.92 | 150,959 | D | — | — | (F1) On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Ordinary Shares | 2025-02-27 | S | D | 1,989 | $20.55 | 148,970 | D | — | — | (F2) On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |